Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Masayuki Kitano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6885-9223; OpenAlex author ID A5067888213, A5103628584, A5121035653, A5137973810. Sources: OpenAlex.

Their work

Papers
54 (first author 8, last author 21)
Trials
0
Grants
0
Labs led
1
Collaborators
169
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 5 papers · 2018: 4 papers · 2019: 6 papers · 2020: 4 papers · 2021: 5 papers · 2022: 5 papers · 2023: 5 papers · 2024: 1 paper · 2025: 4 papers · 2026: 8 papers

Papers 50 of 54

  1. Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S-1, Irinotecan, and Oxaliplatin as Second-Line Chemotherapy After Gemcitabine Plus Nab… Last author DOI 10.1002/jhbp.70122↗
  2. Reply to "Prognostic value of functional assessment in sarcopenia among pancreatic cancer patients". Last author DOI 10.1007/s00535-026-02446-w↗
  3. Contrast-enhanced harmonic endoscopic ultrasonography (EUS)-guided tissue acquisition significantly improves diagnostic yield for small liver metastases derive… Last author DOI 10.1016/j.pan.2025.12.001↗
  4. Establishment of simple pancreatic ductal adenocarcinoma identification method: S100P measurement in duodenal fluid obtained during upper gastrointestinal endo… Co-author DOI 10.1016/j.pan.2025.12.020↗
  5. Clinical Practice Guidelines for Pancreatic Cancer 2025 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000002600↗
  6. Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicenter Analysis by the Japan Study Group on E… Co-author DOI 10.1097/mpa.0000000000002710↗
  7. KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006645↗
  8. Impact of Stent Type on Surgical Outcomes in Pancreatic Cancer Patients Undergoing Preoperative Biliary Drainage. Co-author DOI 10.1111/den.70229↗
  9. Impact of sarcopenia and changes in skeletal muscle mass on prognosis of patients with pancreatic ductal adenocarcinoma receiving chemotherapy with first-line … Last author DOI 10.1007/s00535-025-02283-3↗
  10. Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome. Last author DOI 10.1007/s10147-025-02905-z↗
  11. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  12. Endoscopic biliary drainage for distal bile duct obstruction due to pancreatic cancer. First author DOI 10.5946/ce.2023.294↗
  13. K-ras gene mutation analysis to diagnosis pancreatic adenocarcinoma from endoscopic ultrasound-guided tissue acquisition; a systematic review and meta-analysis. Last author DOI 10.1016/j.pan.2023.11.012↗
  14. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  15. Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomiz… Co-author DOI 10.1002/jgh3.12966↗
  16. Gastrojejunostomy versus endoscopic duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer: a propensity score… Last author DOI 10.1007/s00464-022-09685-x↗
  17. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  18. Utility of contrast-enhanced harmonic endoscopic ultrasonography for prediction of pathological response after neoadjuvant chemotherapy in patients with pancre… Last author DOI 10.1016/j.pan.2023.10.016↗
  19. Efficacy of EUS-guided celiac plexus neurolysis in combination with EUS-guided celiac ganglia neurolysis for pancreatic cancer-associated pain: a multicenter p… Last author DOI 10.1007/s10147-022-02160-6↗
  20. Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gem… Last author DOI 10.1016/j.pan.2021.12.013↗
  21. Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cance… Last author DOI 10.1016/j.pan.2022.04.005↗
  22. Endoscopic ultrasound-guided tissue acquisition for pancreatic ductal adenocarcinoma in the era of precision medicine. First author DOI 10.1111/den.14344↗
  23. Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer. Last author DOI 10.3390/cancers14030551↗
  24. Computed tomography findings for predicting the future occurrence of pancreatic cancer: value of pancreatic volumetry. Last author DOI 10.1007/s10147-021-01915-x↗
  25. Improved detection of liver metastasis using Kupffer-phase imaging in contrast-enhanced harmonic EUS in patients with pancreatic cancer (with video). First author DOI 10.1016/j.gie.2020.06.051↗
  26. Value of Low-Mechanical-Index Contrast-Enhanced Transabdominal Ultrasound for Diagnosis of Pancreatic Cancer: A Meta-analysis. Last author DOI 10.1016/j.ultrasmedbio.2021.08.005↗
  27. Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline rese… Last author DOI 10.1111/den.13926↗
  28. Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: A prospective study. Last author DOI 10.1111/jgh.15661↗
  29. Fully covered self-expandable metal stent with an anti-migration system vs plastic stent for distal biliary obstruction caused by borderline resectable pancrea… Last author DOI 10.1097/md.0000000000018718↗
  30. Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000001513↗
  31. Can early diagnosis of EUS‐FNA needle tract seeding for pancreatic cancer improve patient prognosis? First author DOI 10.1111/den.13719↗
  32. Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasonography for Early Diagnosis of Small Pancreatic Cancer. Last author DOI 10.3390/diagnostics10010023↗
  33. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. Co-author DOI 10.1007/s00535-018-1519-2↗
  34. Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.dld.2019.03.015↗
  35. Value of contrast-enhanced harmonic endoscopic ultrasonography with enhancement pattern for diagnosis of pancreatic cancer: A meta-analysis. Last author DOI 10.1111/den.13290↗
  36. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  37. Advances in Early Detection of Pancreatic Cancer. Last author DOI 10.3390/diagnostics9010018↗
  38. Endoscopic Ultrasound for Early Diagnosis of Pancreatic Cancer. Last author DOI 10.3390/diagnostics9030081↗
  39. Outcomes of endoscopic biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: a multicenter cohort study in West Japan. First author DOI 10.1016/j.gie.2018.01.021↗
  40. Multicenter study of early pancreatic cancer in Japan. Co-author DOI 10.1016/j.pan.2017.11.007↗
  41. Utility of Endoscopic Ultrasonography Screening for Small Pancreatic Cancer and Proposal for a New Scoring System for Screening. Co-author DOI 10.1097/mpa.0000000000000988↗
  42. Alleviating Pancreatic Cancer-Associated Pain Using Endoscopic Ultrasound-Guided Neurolysis. Co-author DOI 10.3390/cancers10020050↗
  43. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
  44. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2016.436↗
  45. A Social Program for the Early Detection of Pancreatic Cancer: The Kishiwada Katsuragi Project. Co-author DOI 10.1159/000481239↗
  46. Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
  47. Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. Co-author DOI 10.3892/ijo.2017.3961↗
  48. Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancer. First author DOI 10.1177/1756283x16644248↗
  49. Surgically resected needle tract seeding following endoscopic ultrasound-guided fine-needle aspiration in pancreatic cancer. First author DOI 10.1002/jhbp.269↗
  50. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2014.10.037↗

Closest collaborators

The 25 strongest of 169 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Reiko Ashida · 17 shared papers, 2017–2026 · strength 3.22
  2. Takashi Tamura · 17 shared papers, 2019–2026 · strength 2.94
  3. Masahiro Itonaga · 15 shared papers, 2019–2026 · strength 2.85
  4. Yasunobu Yamashita · 17 shared papers, 2019–2026 · strength 2.71
  5. Yuki Kawaji · 13 shared papers, 2020–2026 · strength 2.20
  6. Tomoya Emori · 10 shared papers, 2021–2026 · strength 1.76
  7. Mamoru Takenaka · 11 shared papers, 2018–2026 · strength 1.50
  8. Keiichi Hatamaru · 11 shared papers, 2019–2023 · strength 1.44
  9. Keiji Hanada · 9 shared papers, 2017–2026 · strength 1.35
  10. Masatoshi Kudo · 15 shared papers, 2011–2023 · strength 1.17
  11. Manabu Kawai · 9 shared papers, 2020–2023 · strength 1.09
  12. Chigusa Morizane · 4 shared papers, 2017–2026 · strength 0.84
  13. Takao Ohtsuka · 4 shared papers, 2018–2026 · strength 0.79
  14. Kosuke Minaga · 8 shared papers, 2015–2023 · strength 0.75
  15. Ken Kamata · 8 shared papers, 2011–2023 · strength 0.69
  16. Hiroki Yamaue · 7 shared papers, 2017–2023 · strength 0.67
  17. Atsushi Masamune · 4 shared papers, 2018–2026 · strength 0.58
  18. Kentaro Yamao · 6 shared papers, 2016–2023 · strength 0.52
  19. Kazuo Hara · 3 shared papers, 2019–2026 · strength 0.52
  20. Takeshi Ogura · 3 shared papers, 2022–2026 · strength 0.50
  21. Ippei Matsumoto · 3 shared papers, 2021–2026 · strength 0.47
  22. Noboru Ideno · 2 shared papers, 2026 · strength 0.46
  23. Akinori Shimizu · 2 shared papers, 2026 · strength 0.43
  24. Atsushi Kanno · 3 shared papers, 2018–2026 · strength 0.41
  25. Atsushi Nakai · 4 shared papers, 2018–2023 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.